A Study of BCMA/CD19 Dual-Target CAR-T Cell Immunotherapy for Relapsed or Refractory Multiple Myeloma
Clinical trial NCT04182581 · UNKNOWN
Trial details
- NCT number
- NCT04182581
- Sponsor
- Xijing Hospital
- Status
- UNKNOWN
- Phase
- Early Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2019-10-15
- Primary completion
- 2020-09-01
- Enrollment
- 18
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.